BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsang CM, Lui VWY, Bruce JP, Pugh TJ, Lo KW. Translational genomics of nasopharyngeal cancer. Semin Cancer Biol 2020;61:84-100. [PMID: 31521748 DOI: 10.1016/j.semcancer.2019.09.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Bauer M, Jasinski-Bergner S, Mandelboim O, Wickenhauser C, Seliger B. Epstein-Barr Virus-Associated Malignancies and Immune Escape: The Role of the Tumor Microenvironment and Tumor Cell Evasion Strategies. Cancers (Basel) 2021;13:5189. [PMID: 34680337 DOI: 10.3390/cancers13205189] [Reference Citation Analysis]
2 Xue WQ, Wang TM, Huang JW, Zhang JB, He YQ, Wu ZY, Liao Y, Yuan LL, Mu J, Jia WH. A comprehensive analysis of genetic diversity of EBV reveals potential high-risk subtypes associated with nasopharyngeal carcinoma in China. Virus Evol 2021;7:veab010. [PMID: 34567789 DOI: 10.1093/ve/veab010] [Reference Citation Analysis]
3 Lu HQ, Wang RK, Wang HR, Zhou GQ, Zhang YS. miR-137 Inhibition of the Invasion, Metastasis, and Epithelial-Mesenchymal Transition of Nasopharyngeal Cancer by Regulating KDM1A. J Oncol 2021;2021:6060762. [PMID: 34956364 DOI: 10.1155/2021/6060762] [Reference Citation Analysis]
4 Xue Z, Lui VWY, Li Y, Jia L, You C, Li X, Piao W, Yuan H, Khong PL, Lo KW, Cheung LWT, Lee VHF, Lee AWM, Tsao SW, Tsang CM. Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma. J Exp Clin Cancer Res 2020;39:262. [PMID: 33243298 DOI: 10.1186/s13046-020-01763-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Baloche V, Ferrand FR, Makowska A, Even C, Kontny U, Busson P. Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges. Expert Opin Ther Targets 2020;24:545-58. [PMID: 32249657 DOI: 10.1080/14728222.2020.1751820] [Reference Citation Analysis]
6 Shi X, Pan J, Qiu F, Wu L, Zhang X, Feng Y, Gu X, Zhao J, Zheng W. Multiscale Transcriptomic Integration Reveals B-Cell Depletion and T-Cell Mistrafficking in Nasopharyngeal Carcinoma Progression. Front Cell Dev Biol 2022;10:857137. [DOI: 10.3389/fcell.2022.857137] [Reference Citation Analysis]
7 Islam KA, Chow LK, Kam NW, Wang Y, Chiang CL, Choi HC, Xia Y, Lee AW, Ng WT, Dai W. Prognostic Biomarkers for Survival in Nasopharyngeal Carcinoma: A Systematic Review of the Literature. Cancers 2022;14:2122. [DOI: 10.3390/cancers14092122] [Reference Citation Analysis]
8 Wu M, Yang L, Hou X, Wang Z, Zhang J. Human Polycomb Protein 2 (hPC2) as a Novel Independent Prognostic Marker in Nasopharyngeal Carcinoma. Cancer Manag Res 2021;13:5775-84. [PMID: 34321924 DOI: 10.2147/CMAR.S308884] [Reference Citation Analysis]
9 Li P, Zhu K, Mo Y, Deng X, Jiang X, Shi L, Guo C, Zhang W, Zeng Z, Li G, Xiong W, Zhang S, Gong Z. Research Progress of circRNAs in Head and Neck Cancers. Front Oncol 2021;11:616202. [PMID: 33996542 DOI: 10.3389/fonc.2021.616202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Looi CK, Hii LW, Chung FF, Mai CW, Lim WM, Leong CO. Roles of Inflammasomes in Epstein-Barr Virus-Associated Nasopharyngeal Cancer. Cancers (Basel) 2021;13:1786. [PMID: 33918087 DOI: 10.3390/cancers13081786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Animesh S, Choudhary R, Wong BJH, Koh CTJ, Ng XY, Tay JKX, Chong WQ, Jian H, Chen L, Goh BC, Fullwood MJ. Profiling of 3D Genome Organization in Nasopharyngeal Cancer Needle Biopsy Patient Samples by a Modified Hi-C Approach. Front Genet 2021;12:673530. [PMID: 34539729 DOI: 10.3389/fgene.2021.673530] [Reference Citation Analysis]
12 Liao W, He J, Liu Z, Tian M, Yang J, Han J, Xiao J. A novel dosimetric metrics-based risk model to predict local recurrence in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. Radiat Oncol 2021;16:186. [PMID: 34556123 DOI: 10.1186/s13014-021-01911-5] [Reference Citation Analysis]
13 Tian Y, Sun Y, Wu J, Xiong Z, Niu F, Li H, Liu Y, Liu J, Cai J. Impact of IL1R1 polymorphisms on the risk of head and neck cancer in Chinese Han population. Gene 2020;757:144927. [PMID: 32628975 DOI: 10.1016/j.gene.2020.144927] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Lung RW, Tong JH, Ip LM, Lam KH, Chan AW, Chak WP, Chung LY, Yeung WW, Hau PM, Chau SL, Tsao SW, Lau KM, Lo KW, To KF. EBV-encoded miRNAs can sensitize nasopharyngeal carcinoma to chemotherapeutic drugs by targeting BRCA1. J Cell Mol Med 2020;24:13523-35. [PMID: 33074587 DOI: 10.1111/jcmm.16007] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Chang SL, Chan TC, Chen TJ, Yang CC, Tsai HH, Yeh CF, Lee SW, Lai HY. High SPIN4 Expression Is Linked to Advanced Nodal Status and Inferior Prognosis in Nasopharyngeal Carcinoma Patients. Life (Basel) 2021;11:912. [PMID: 34575061 DOI: 10.3390/life11090912] [Reference Citation Analysis]
16 Zhou D, Ye C, Pan Z, Deng Y. SATB1 Knockdown Inhibits Proliferation and Invasion and Decreases Chemoradiation Resistance in Nasopharyngeal Carcinoma Cells by Reversing EMT and Suppressing MMP-9. Int J Med Sci 2021;18:42-52. [PMID: 33390772 DOI: 10.7150/ijms.49792] [Reference Citation Analysis]
17 Johnson D, Ma BBY. Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma. Oral Oncol 2021;113:105127. [PMID: 33454551 DOI: 10.1016/j.oraloncology.2020.105127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Bruce JP, To KF, Lui VWY, Chung GTY, Chan YY, Tsang CM, Yip KY, Ma BBY, Woo JKS, Hui EP, Mak MKF, Lee SD, Chow C, Velapasamy S, Or YYY, Siu PK, El Ghamrasni S, Prokopec S, Wu M, Kwan JSH, Liu Y, Chan JYK, van Hasselt CA, Young LS, Dawson CW, Paterson IC, Yap LF, Tsao SW, Liu FF, Chan ATC, Pugh TJ, Lo KW. Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape. Nat Commun 2021;12:4193. [PMID: 34234122 DOI: 10.1038/s41467-021-24348-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Young LS. A novel Epstein-Barr virus subtype associated with nasopharyngeal carcinoma found in South China. Cancer Commun (Lond) 2020;40:60-2. [PMID: 32077639 DOI: 10.1002/cac2.12006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
20 Siak PY, Khoo AS, Leong CO, Hoh BP, Cheah SC. Current Status and Future Perspectives about Molecular Biomarkers of Nasopharyngeal Carcinoma. Cancers (Basel) 2021;13:3490. [PMID: 34298701 DOI: 10.3390/cancers13143490] [Reference Citation Analysis]
21 Dang Q, Shao B, Zhou Q, Chen C, Guo Y, Wang G, Liu J, Kan Q, Yuan W, Sun Z. RNA N 6-Methyladenosine in Cancer Metastasis: Roles, Mechanisms, and Applications. Front Oncol 2021;11:681781. [PMID: 34211849 DOI: 10.3389/fonc.2021.681781] [Reference Citation Analysis]
22 De Re V, Caggiari L, De Zorzi M, Fanotto V, Miolo G, Puglisi F, Cannizzaro R, Canzonieri V, Steffan A, Farruggia P, Lopci E, d'Amore ESG, Burnelli R, Mussolin L, Mascarin M. Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer. Infect Agent Cancer 2020;15:42. [PMID: 32582365 DOI: 10.1186/s13027-020-00307-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
23 Buonsenso D, Gennaro LD, Rose C, Morello R, D'Ilario F, Zampino G, Piazza M, Boner AL, Iraci C, O'Connell S, Cohen VB, Esposito S, Munblit D, Reena J, Sigfrid L, Valentini P. Long-term outcomes of pediatric infections: from traditional infectious diseases to long covid. Future Microbiol 2022. [PMID: 35264003 DOI: 10.2217/fmb-2022-0031] [Reference Citation Analysis]
24 Hau PM, Lung HL, Wu M, Tsang CM, Wong KL, Mak NK, Lo KW. Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma. Front Oncol 2020;10:600. [PMID: 32528868 DOI: 10.3389/fonc.2020.00600] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
25 Zhou DN, Ye CS, Yang QQ, Deng YF. Integrated analysis of transcriptome profiling predicts potential lncRNA and circRNA targets in human nasopharyngeal carcinoma. Oncol Lett 2020;19:3123-36. [PMID: 32218863 DOI: 10.3892/ol.2020.11412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Campion NJ, Ally M, Jank BJ, Ahmed J, Alusi G. The molecular march of primary and recurrent nasopharyngeal carcinoma. Oncogene 2021;40:1757-74. [PMID: 33479496 DOI: 10.1038/s41388-020-01631-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhang SQ, Pan SM, Liang SX, Han YS, Chen HB, Li JC. Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high‑throughput omics (Review). Int J Oncol 2021;58:9. [PMID: 33649830 DOI: 10.3892/ijo.2021.5188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
28 Wong KCW, Hui EP, Lo KW, Lam WKJ, Johnson D, Li L, Tao Q, Chan KCA, To KF, King AD, Ma BBY, Chan ATC. Nasopharyngeal carcinoma: an evolving paradigm. Nat Rev Clin Oncol 2021. [PMID: 34194007 DOI: 10.1038/s41571-021-00524-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zhou Z, Li P, Zhang X, Xu J, Xu J, Yu S, Wang D, Dong W, Cao X, Yan H, Sun M, Ding X, Xing J, Zhang P, Zhai L, Fan T, Tian S, Yang X, Hu M. Mutational landscape of nasopharyngeal carcinoma based on targeted next-generation sequencing: implications for predicting clinical outcomes. Mol Med 2022;28:55. [PMID: 35562651 DOI: 10.1186/s10020-022-00479-4] [Reference Citation Analysis]
30 Huang H, Li S, Tang Q, Zhu G. Metabolic Reprogramming and Immune Evasion in Nasopharyngeal Carcinoma. Front Immunol 2021;12:680955. [PMID: 34566954 DOI: 10.3389/fimmu.2021.680955] [Reference Citation Analysis]
31 Kang Y, He W, Ren C, Qiao J, Guo Q, Hu J, Xu H, Jiang X, Wang L. Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma. Signal Transduct Target Ther 2020;5:245. [PMID: 33093441 DOI: 10.1038/s41392-020-00340-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
32 Emanuel O, Liu J, Schartinger VH, Nei WL, Chan YY, Tsang CM, Riechelmann H, Masterson L, Haybaeck J, Oppermann U, Willems SM, Ooft ML, Wollmann G, Howard D, Vanhaesebroeck B, Lund VJ, Royle G, Chua MLK, Lo KW, Busson P, Lechner M. SSTR2 in Nasopharyngeal Carcinoma: Relationship with Latent EBV Infection and Potential as a Therapeutic Target. Cancers (Basel) 2021;13:4944. [PMID: 34638429 DOI: 10.3390/cancers13194944] [Reference Citation Analysis]
33 Yang L, Liu G, Li Y, Pan Y. The emergence of tumor-infiltrating lymphocytes in nasopharyngeal carcinoma: Predictive value and immunotherapy implications. Genes & Diseases 2021. [DOI: 10.1016/j.gendis.2021.07.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020;6:92. [PMID: 33243986 DOI: 10.1038/s41572-020-00224-3] [Cited by in Crossref: 107] [Cited by in F6Publishing: 112] [Article Influence: 53.5] [Reference Citation Analysis]